Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren’s disease

Abstract

The balance between MMPs and their natural inhibitors is disturbed in patients with Dupuytren's disease. The decrease in MMP-to-TIMP expression can cause increased synthesis and deposition of collagen, leading to palmar fibromatosis. The high expression of MMP2 may represent an unsuccessful attempt to reduce collagen deposition. In the future, a treatment that downregulates TIMPs but increases the activity of MMPs may be an appropriate therapy for Dupuytren's disease.

Systematic review of biochemical biomarkers for neck and upper-extremity musculoskeletal disorders

“…Two studies saw no association with this category of potential biomarkers (49,51). Three studies found increased TIMP (most consistently, TIMP-1) in serum from subjects with adhesive capsulitis, and in serum or palmar fascia from subjects with Dupuytren's contracture (49,50,56). Two of these showed a decreased MMP/TIMP ratio in serum of subjects with fibroproliferative MSD (49,56).…”

“…As shown in table 2, five studies demonstrated a relationship between MSD severity and biomarker concentration (40,41,49,50,76). Six studies investigated biomarker concentration in relation to a severity score or disease stage determined during a physical examination (33,40,45,49,50,73).…”

“…Gold et al Yes biopsies from subjects with Dupuytren's contracture (44,50,73). A study of adhesive capsulitis found reduced MMP in patients (56).…”

“…Six studies investigated biomarker concentration in relation to a severity score or disease stage determined during a physical examination (33,40,45,49,50,73). Increased collagen-repair marker, TIMP-1 (49,50), and a decreased MMP/TIMP ratio (49) were observed at an earlier (more active) Dupuytren's contracture stage. Increased MMP-2, a collagen degradation marker, was found in an earlier stage of Dupuytren's contracture in one study (50), although not in another (73).…”

“…Many studies were conducted in older populations with at least one analysis group >50 years of age (33)(34)(35)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60). The range of symptom duration varied substantially within and across studies.…”